Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Neuropharmacology ; 103: 290-305, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26686390

RESUMO

Alterations in rapid eye movement sleep (REM) have been suggested as valid translational efficacy markers: activation of the metabotropic glutamate receptor 2 (mGluR2) was shown to increase REM latency and to decrease REM duration. The present paper addresses the effects on vigilance states of the mGluR2 positive allosteric modulator (PAM) JNJ-40411813 at different circadian times in rats and after afternoon dosing in humans. Due to its dual mGluR2 PAM/serotonin 2A (5-HT2A) receptor antagonism in rodents, mGlu2R specificity of effects was studied in wild-type (WT) and mGluR2 (-/-) mice. 5-HT2A receptor occupancy was determined in humans using positron emission tomography (PET). Tolerance development was examined in rats after chronic dosing. EEG oscillations and network connectivity were assessed using multi-channel EEG. In rats, JNJ-40411813 increased deep sleep time and latency of REM onset but reduced REM time when administered 2 h after 'lights on' (CT2): this was sustained after chronic dosing. At CT5 similar effects were elicited, at CT10 only deep sleep was enhanced. Withdrawal resulted in baseline values, while re-administration reinstated drug effects. Parieto-occipital cortical slow theta and gamma oscillations were correlated with low locomotion. The specificity of functional response was confirmed in WT but not mGluR2 (-/-) mice. A double-blind, placebo-controlled polysomnographic study in healthy, elderly subjects showed that 500 mg of JNJ-40411813 consistently increased deep sleep time, but had no effect on REM parameters. This deep sleep effect was not explained by 5-HT2A receptor binding, as in the PET study even 700 mg only marginally displaced the tracer. JNJ-40411813 elicited comparable functional responses in rodents and men if circadian time of dosing was taken into account. These findings underscore the translational potential of sleep mechanisms in evaluating mGluR2 therapeutics when administered at the appropriate circadian time.


Assuntos
Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/fisiologia , Ritmo Circadiano/efeitos dos fármacos , Piperidinas/administração & dosagem , Piperidinas/sangue , Piperidinas/farmacologia , Piridonas/administração & dosagem , Piridonas/sangue , Piridonas/farmacologia , Receptores de Glutamato Metabotrópico/fisiologia , Sono/efeitos dos fármacos , Adulto , Regulação Alostérica , Animais , Ondas Encefálicas/efeitos dos fármacos , Córtex Cerebral/diagnóstico por imagem , Eletroencefalografia , Humanos , Masculino , Camundongos , Camundongos Knockout , Pessoa de Meia-Idade , Atividade Motora/efeitos dos fármacos , Tomografia por Emissão de Pósitrons , Ratos , Ratos Sprague-Dawley , Receptor 5-HT2A de Serotonina/metabolismo , Receptores de Glutamato Metabotrópico/genética , Antagonistas do Receptor 5-HT2 de Serotonina/administração & dosagem , Sono REM/efeitos dos fármacos , Pesquisa Translacional Biomédica , Adulto Jovem
2.
Curr Med Chem ; 18(1): 47-68, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21110815

RESUMO

The metabotropic glutamate type 2 (mGlu2) receptor is a G-protein coupled receptor (GPCR) expressed on presynaptic nerve terminals where it negatively modulates glutamate and GABA release. Mixed mGlu2/mGlu3 orthosteric agonists such as LY354740 have shown activity in a range of preclinical animal models of anxiety and schizophrenia. Clinical work with LY354740 demonstrated activity in a CO(2) inhalation study suggesting application in the treatment of anxiety related disorders. Subsequently, a related prodrug LY2140023 demonstrated improvements in positive and negative symptoms in patients suffering from schizophrenia. These molecules exhibit combined mGlu2/mGlu3 activity although there is evidence from knock-out studies that preclinical anti-psychotic effects may be mediated via the mGlu2 receptor. An alternative avenue for modulating GPCRs is to act via allosteric mechanisms, binding at a different site from the orthosteric agonist. Since the first discovery of mGlu2 positive allosteric modulators (PAMs) such as 2,2,2-TEMPS and BINA, multiple families of mGlu2 modulators have been reported and several have entered into clinical development. This review focuses on recent advances in the development of novel mGlu2 PAMs by analysis of compounds disclosed in research articles and patent literature between 2007 and 2010.


Assuntos
Receptores de Glutamato Metabotrópico/agonistas , Acetofenonas/química , Acetofenonas/farmacologia , Regulação Alostérica , Benzimidazóis/química , Benzimidazóis/farmacologia , Compostos Bicíclicos com Pontes/química , Compostos Bicíclicos com Pontes/farmacologia , Carbamatos/química , Carbamatos/farmacologia , Isoindóis/química , Isoindóis/farmacologia , Piridinas/química , Piridinas/farmacologia , Piridonas/química , Piridonas/farmacologia , Receptores de Glutamato Metabotrópico/metabolismo
11.
An. cir.(Rosario) ; 31(1): 11-8, 1966 Jan-Jun.
Artigo em Espanhol | LILACS-Express | BINACIS | ID: biblio-1159154
12.
An Cir [Rosario] ; 31(1): 11-8, 1966 Jan-Jun.
Artigo em Espanhol | BINACIS | ID: bin-40591
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...